Cost-Effectiveness of Dapagliflozin as Add-On to Metformin for the Treatment of Type 2 Diabetes Mellitus in Greece

被引：0
|
作者：
Charalampos Tzanetakos
Nicholas Tentolouris
Georgia Kourlaba
Nikos Maniadakis
机构：
[1] National School of Public Health,Department of Health Services Organization and Management
[2] National and Kapodistrian University of Athens,First Department of Propaedeutic and Internal Medicine, Medical School
[3] Laiko General Hospital,Collaborative Center for Clinical Epidemiology and Outcomes Research (CLEO)
[4] “Aghia Sophia” Children`s Hospital,undefined
来源：
Clinical Drug Investigation | 2016年 / 36卷
关键词：
Metformin; Hypoglycemic Event; Probabilistic Sensitivity Analysis; United Kingdom Prospective Diabetes Study; Drug Acquisition Cost;
D O I：
暂无
中图分类号：
学科分类号：
摘要：
引用
收藏
页码：649 / 659
页数：10
相关论文
共 50 条
  • [21] DAPAGLIFLOZIN VERSUS SULFONYLUREA AS AN ADD-ON THERAPY TO METFORMIN: A COST-EFFECTIVENESS ANALYSIS IN COLOMBIA
    Elgart, J. F.
    Prestes, M.
    Gonzalez, L.
    Aschner, P.
    Garrido Lecca, S.
    Aiello, E.
    Jimenez, C.
    Gagliardino, J. J.
    [J]. VALUE IN HEALTH, 2014, 17 (03) : A247 - A247
  • [22] Cost-effectiveness and clinical outcomes of metformin or insulin add-on therapy in adults with type 2 diabetes
    Brown, RR
    [J]. AMERICAN JOURNAL OF HEALTH-SYSTEM PHARMACY, 1998, 55 : S24 - S27
  • [23] COST-EFFECTIVENESS ANALYSIS OF CANAGLIFLOZIN (CANA) VERSUS DAPAGLIFLOZIN (DAPA) AS AN ADD-ON TO METFORMIN (MET) IN PATIENTS WITH TYPE 2 DIABETES MELLITUS (T2DM) IN THE UNITED STATES
    Neslusan, C.
    Teschemaker, A.
    Martin, S.
    Willis, M.
    Johansen, P.
    [J]. VALUE IN HEALTH, 2014, 17 (03) : A248 - A248
  • [24] COST-EFFECTIVENESS ANALYSIS OF DAPAGLIFLOZIN IN THE TREATMENT OF TYPE-2 DIABETES MELLITUS IN SPAIN
    Capel, M.
    Pomares, E.
    Perez-Alcantara, F.
    Simon, S.
    [J]. VALUE IN HEALTH, 2020, 23 : S508 - S508
  • [25] Cost-effectiveness of Empagliflozin Compared with Dapagliflozin for the Treatment of Patients with Type 2 Diabetes Mellitus and Established Cardiovascular Disease in Greece
    Gourzoulidis, George
    Tzanetakos, Charalampos
    Ioannidis, Ioannis
    Tsimihodimos, Vasilis
    Diogo, Viana
    Karpouzos, George
    Papageorgiou, Giannis
    Kourlaba, Georgia
    [J]. CLINICAL DRUG INVESTIGATION, 2021, 41 (04) : 371 - 380
  • [26] DAPAGLIFLOZIN VERSUS SULFONYLUREA AS AN ADD-ON THERAPY TO METFORMIN: A COST-EFFECTIVENESS ANALYSIS IN COSTA RICA
    Elgart, J. F.
    Gonzalez, L.
    Prestes, M.
    Vinocour, M.
    Solorzano, J.
    Gagliardino, J. J.
    [J]. VALUE IN HEALTH, 2016, 19 (03) : A202 - A202
  • [27] Cost-effectiveness of Empagliflozin Compared with Dapagliflozin for the Treatment of Patients with Type 2 Diabetes Mellitus and Established Cardiovascular Disease in Greece
    George Gourzoulidis
    Charalampos Tzanetakos
    Ioannis Ioannidis
    Vasilis Tsimihodimos
    Viana Diogo
    George Karpouzos
    Giannis Papageorgiou
    Georgia Kourlaba
    [J]. Clinical Drug Investigation, 2021, 41 : 371 - 380
  • [28] Cost-effectiveness analysis of dapagliflozin treatment versus metformin treatment in Chinese population with type 2 diabetes
    Cai, Xiaoling
    Shi, Lizheng
    Yang, Wenjia
    Gu, Shuyan
    Chen, Yingyao
    Nie, Lin
    Ji, Linong
    [J]. JOURNAL OF MEDICAL ECONOMICS, 2019, 22 (04) : 336 - 343
  • [29] Cost-Utility Analysis of Dapagliflozin Versus Saxagliptin Treatment as Monotherapy or Combination Therapy as Add-on to Metformin for Treating Type 2 Diabetes Mellitus
    Shanshan Hu
    Xun Deng
    Yanjiao Ma
    Zhilei Li
    Yuhang Wang
    Yong Wang
    [J]. Applied Health Economics and Health Policy, 2021, 19 : 69 - 79
  • [30] Cost-Utility Analysis of Dapagliflozin Versus Saxagliptin Treatment as Monotherapy or Combination Therapy as Add-on to Metformin for Treating Type 2 Diabetes Mellitus
    Hu, Shanshan
    Deng, Xun
    Ma, Yanjiao
    Li, Zhilei
    Wang, Yuhang
    Wang, Yong
    [J]. APPLIED HEALTH ECONOMICS AND HEALTH POLICY, 2021, 19 (01) : 69 - 79
12345